LEADER 04309nam 2201141z- 450 001 9910619467903321 005 20231214133313.0 010 $a3-0365-5060-7 035 $a(CKB)5670000000391595 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/93181 035 $a(EXLCZ)995670000000391595 100 $a20202210d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aGluten-Related Disorders: Time to Move from Gut to Brain 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (158 p.) 311 $a3-0365-5059-3 330 $aThe extraintestinal manifestations of coeliac disease (CD) are now well recognised. We have previously edited a special issue for Nutrients covering all aspects of the extraintestinal manifestations in the context of CD. In this issue we wish to concentrate just on the neurological manifestations. The identification of TG6 autoantibodies in patients with neurological manifestations and its use in the diagnosis of such patients seems to be a good opportunity to focus on the neurological aspect of CD. In addition it is now clear that such manifestations can occur even in the absence of enteropathy but in the presence of antigliadin antibodies and/or TG6 antibodies. Given that such antigliadin antibodies can be found in up to 10% of the ?healthy? population we anticipate that the neurological manifestations are likely to be very common and thus merit early recognition and treatment. 517 $aGluten-Related Disorders 606 $aResearch & information: general$2bicssc 606 $aBiology, life sciences$2bicssc 606 $aFood & society$2bicssc 610 $acoeliac disease 610 $agluten free diet 610 $apsychiatric manifestations 610 $aautistic spectrum disorder 610 $aattention deficit hyperactivity disorder 610 $adepression 610 $aanxiety 610 $abipolar disorder 610 $aschizophrenia 610 $aeating disorders 610 $agluten 610 $aneurological disorders 610 $agliadin 610 $aataxia 610 $aneuropathy 610 $amyopathy 610 $aencephalopathy 610 $afood intolerance 610 $aceliac disease 610 $agluten sensitivity 610 $agluten-free diet 610 $acognition 610 $aneurology 610 $adisease duration 610 $aautoimmunity 610 $amultiple sclerosis 610 $apsoriasis 610 $aautoimmune thyroid disease 610 $atype 1 diabetes 610 $atransglutaminase antibodies 610 $aTG2 610 $aTG3 610 $aTG6 610 $adermatitis herpetiformis 610 $agluten ataxia 610 $agluten encephalopathy 610 $agluten neuropathy 610 $aautism spectrum disorder 610 $areview 610 $astiff person syndrome 610 $aanti-GAD antibodies 610 $acerebellar ataxia 610 $agluten-related pathology 610 $acortical excitability 610 $atranscallosal inhibition 610 $atranscranial magnetic stimulation 610 $aexecutive dysfunction 610 $agamma-amino-butyric acid 610 $aneurological dysfunction 610 $aheadaches 610 $aanti-gliadin antibodies 610 $aMR imaging 610 $aTG6 antibodies 610 $anon-celiac wheat sensitivity 610 $airritable bowel syndrome 610 $amultiple food hypersensitivity 610 $aneuropsychiatric symptoms 610 $aHLA 610 $aduodenal lymphocytosis 615 7$aResearch & information: general 615 7$aBiology, life sciences 615 7$aFood & society 700 $aHoggard$b Nigel$4edt$01329057 702 $aSanders$b David$4edt 702 $aHadjivassiliou$b Marios$4edt 702 $aHoggard$b Nigel$4oth 702 $aSanders$b David$4oth 702 $aHadjivassiliou$b Marios$4oth 906 $aBOOK 912 $a9910619467903321 996 $aGluten-Related Disorders: Time to Move from Gut to Brain$93039280 997 $aUNINA